Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.19.1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
 9 Months Ended 12 Months Ended
Feb. 28, 2019
May 31, 2016
Commitments and Contingencies [Line Items]    
Asset Purchase Agreement Aggregate Consideration Paying Period 10 years  
Payment to acquire other assets   $ 1,500,000
Minimum    
Commitments and Contingencies [Line Items]    
Royalty on every net sales 0.75%  
Maximum    
Commitments and Contingencies [Line Items]    
Royalty on every net sales 2.00%  
Development Milestone Payments    
Commitments and Contingencies [Line Items]    
Asset Purchase Agreement Aggregate Consideration Paying Period 10 years  
Minimum annual license maintenance fees $ 150,000  
Project Work Order | Termination of Any One Clinical Trial | Maximum    
Commitments and Contingencies [Line Items]    
Financial penalties 300,000  
Project Work Order | Termination of All Clinical Trials | Minimum    
Commitments and Contingencies [Line Items]    
Financial penalties 500,000  
Project Work Order | Termination of All Clinical Trials | Maximum    
Commitments and Contingencies [Line Items]    
Financial penalties 1,200,000  
Contract Manufacturing Companies    
Commitments and Contingencies [Line Items]    
Execution fees for process validation and manufacturing activities 2,100,000  
Contract Manufacturing Companies | Termination of Any One Clinical Trial | Maximum    
Commitments and Contingencies [Line Items]    
Financial penalties 300,000  
Biologic License Application with the FDA or Non-U.S. Equivalent Regulatory Body | Milestone Payments    
Commitments and Contingencies [Line Items]    
Potential future milestone and royalties payments 500,000  
First U.S. New Drug Application Approval by the FDA or Other Non-U.S. Approval | Milestone Payments    
Commitments and Contingencies [Line Items]    
Potential future milestone and royalties payments $ 5,000,000  
Royalty on every net sales 5.00%  
FDA Approval or Approval by Another Non-U.S. Equivalent Regulatory Body | Development Milestone Payments    
Commitments and Contingencies [Line Items]    
Potential future milestone and royalties payments $ 500,000  
Royalty on every net sales 3.50%